Prognosis in advanced lung cancer – A prospective study examining key clinicopathological factors

Simmons, Claribel; Koinis, Filippos; Fallon, Marie; Fearon, K. C. H.; Bowden, Jo; Solheim, Tora Skeidsvoll; Grønberg, Bjørn Henning; McMillan, Donald C.; Gioulbasanis, Ioannis; Laird, Barry

doi:10.1016/j.lungcan.2015.03.020

Cited by 106 publications

(87 citation statements)

References 19 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Low BMI, weight loss, and PS have long been regarded as major prognostic factors in lung cancer . Our study found that low BMI as well as poor PS were risk factors for treatment refusal in cancer.…”

Section: Discussionmentioning

confidence: 50%

Risk factors associated with treatment refusal in lung cancer

et al. 2017

View full text Add to dashboard Cite

BackgroundThe incidence of lung cancer is increasing with longer life expectancy. Refusal of active treatment for cancer is prone to cause patients to experience more severe symptoms and shorten survival. The purpose of this study was to define the factors related to refusal or abandonment of active therapy in lung cancer.MethodsWe retrospectively reviewed the data of 617 patients from medical records from 2010 to 2014. Two groups were formed: 149 patients who refused anti‐cancer treatment and allowed only palliative care were classified into the non‐treatment group, while the remaining 468 who received anti‐cancer treatment were classified into the treatment group.ResultsThe groups differed significantly in age, employment, relationship status, number of offspring, educational status, body mass index, presence of chest and systemic symptoms, Charlson Comorbidity Index, Eastern Cooperative Oncology Group score, and tumor node metastasis stage (P < 0.05). In logistic regression analysis, age (odds ratio [OR] 1.10, 95% confidence interval [CI] 1.07–1.13), educational status lower than high school (OR 1.95, 95% CI 1.2–3.2), no history of surgery (OR 2.29, 95% CI 1.4–3.7), body mass index < 18.5 (OR 2.49, 95% CI 1.3–4.7), and a high Eastern Cooperative Oncology Group score of 3 or 4 (OR 5.02, 95% CI 2.3–10.8) were significant factors for refusal of cancer treatment.ConclusionIndividual factors, such as old age, low educational status, low weight, and poor performance status can influence refusal of cancer treatment in patients with lung cancer, and should be considered prior to consultation with patients.

show abstract

Section: Discussionmentioning

confidence: 50%

Risk factors associated with treatment refusal in lung cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Another defect is that we only recorded overall survival, not time to disease progression, as this parameter is recorded by oncologists and the information was not available at the time of the follow‐up visits. Another limitation is the absence of registration of comorbidities, which could have biased our results …”

Section: Discussionmentioning

confidence: 99%

“…Another limitation is the absence of registration of comorbidities, which could have biased our results. 14 In summary, SCLC diagnosis and treatment has changed over the last years, because of improved techniques which can better characterise the initial disease extension. Some of these factors improve the likelihood of survival during the follow-up period.…”

Section: Pet-ct Not Performed (N = 11)mentioning

confidence: 99%

“…6,12 However, even in the light of recent progress, there is still a lack of data on how these new approaches have been translated into daily clinical practice and whether or not they have improved the prognosis for patients with SCLC. Some studies have observed changes in the clinical presentation and overall course of SCLC, [12][13][14] but we are still unaware as to whether those changes affected patient survival in Spain.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Small cell lung cancer: Recent changes in clinical presentation and prognosis

Vázquez

Flores

Ortiz

et al. 2020

Clinical Respiratory J

View full text Add to dashboard Cite

Background Small cell lung cancer (SCLC) is a leading cause of death all over the world. Diagnostic and therapeutic arsenals have improved in recent years, but we are unsure as to whether these advances have been transferred to clinical practice. The aim of this study was to evaluate differences in SCLC diagnostic processes and short‐term survival rates between two recent cohorts. Methods A prospective, observational study was conducted with patients diagnosed with SCLC (either at extensive or limited stages) in the 2011‐2016 period. Patients were divided into two cohorts (2011‐2013 and 2014‐2016) and followed up for 1 year after diagnosis. Results Around 713 patients with lung cancer were selected, 134 of whom had SCLC (74 patients in the 2011‐2013 cohort and 60 in the 2014‐2016 cohort). We observed a chronological increase in the use of endobronchial ultrasound transbronchial needle aspiration (EBUS‐TBNA) and positron emission tomography‐computed tomography (PET‐CT) between the cohorts. Overall, short‐term survival was similar between the two groups and improved survival was associated with age and limited stage. Conclusions Changes in diagnostic process in SCLC have been observed towards a more precise stadification. Although short‐term survival has not changed for SCLC, it is unclear that the real benefit of PET‐CT and EBUS‐TBNA is far from correct disease staging.

show abstract

“…Along these same lines, an unexpectedly good prognosis has been reported in non-small cell lung cancer (NSCLC) patients with minimal carcinomatous pleuritis (4), although surgery alone is not considered a suitable choice for NSCLC with pleural dissemination. In other words, multimodal therapeutic approaches combining surgery, chemotherapy, radiotherapy, targeted therapy, or supportive care may all be beneficial for treating advanced-stage lung cancer (5).…”

Section: Introductionmentioning

confidence: 99%

Clinical outcomes of cytoreductive surgery combined with intrapleural perfusion of hyperthermic chemotherapy in advanced lung adenocarcinoma with pleural dissemination

Kim

Cho

et al. 2016

J. Thorac. Dis.

View full text Add to dashboard Cite

Background: This study aimed to investigate the safety and feasibility of intrapleural perfusion hyperthermic chemotherapy (IPHC) followed by cytoreductive surgery as a part of multimodal strategy for the treatment of advanced lung adenocarcinoma. Methods: Medical records of advanced lung cancer patients with pleural dissemination who underwent surgical treatment between 2003 and 2013 were reviewed retrospectively. Enrolled patients were divided into a surgery group comprising patients who underwent surgery only and an IPHC group, which consisted of patients who underwent surgery combined with IPHC. Results: A total of 33 patients were enrolled in this study. Twenty-three patients underwent IPHC after surgical resection, and 10 patients underwent surgical resection only. The complication rate of the IPHC group was estimated to be 34.8% (8 cases), none of which included postoperative mortality. The complication rate of the surgery group was 40.0% (4 cases), which included one postoperative mortality.The 6-month, 1-year, and 3-year overall survival rates for the IPHC group were 95.7%, 91.3% and 38.6%, respectively, while those of the surgery group were 80.0%, 80.0% and 37.5%. The 6-month, 1-year and 3-year progression-free survival rates for the IPHC group were 87.0%, 47.8% and 24.3%, while those of surgery group were 44.4%, 33.3% and 0.0%, respectively. There were significant differences in overall survival rates between two groups (P=0.045); however, progression-free survival was not different between the two groups. Conclusions: IPHC combined with cytoreductive surgery for advanced lung adenocarcinoma associated with pleural seeding could be performed safely and feasible. It would be part of multimodality therapy for certain category of advanced lung adenocarcinoma. However, the long-term benefits for survival is uncertain.More extensive and precisely designed studies are warranted to further evaluate the effectiveness of IPHC.

show abstract

Prognosis in advanced lung cancer – A prospective study examining key clinicopathological factors

Abstract: Performance status and the mGPS are superior prognostic factors in advanced lung cancer. In combination, these improved survival prediction compared with either alone.

Cited by 106 publications

References 19 publications

Risk factors associated with treatment refusal in lung cancer

Risk factors associated with treatment refusal in lung cancer

Small cell lung cancer: Recent changes in clinical presentation and prognosis

Clinical outcomes of cytoreductive surgery combined with intrapleural perfusion of hyperthermic chemotherapy in advanced lung adenocarcinoma with pleural dissemination

Contact Info

Product

Resources

About